Rigel Pharmaceuticals Inc. (New) (RIGL) — Analysis Summary
Rigel Pharmaceuticals Inc. (New) (RIGL) has a market cap of $911.76M with year-over-year revenue growth of +64.1%. Net margin stands at 124.7%. The stock trades at a P/E ratio of 2.8.
Key Takeaways
- Revenue changed +64.1% year-over-year
- Net margin of 124.7%
- P/E ratio of 2.8
Compared to other companies in the PHARMACEUTICAL PREPARATIONS sector, RIGL posted revenue growth of +64.1% and trades at a P/E of 2.8.
Rigel Pharmaceuticals Inc. (New) (RIGL)
PREVIOUS CLOSE 2026-10-12 · MARKET DATA POLYGON · FINANCIALS SEC EDGAR
Red Flags & WarningsWatch List
Some caution signals are active and should be weighed alongside the valuation work.
Gross margin at 91.4% — verify: very few businesses sustain >90% gross margin outside pure software/IP
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, REZLIDHIA (olutasidenib), GAVRETO (pralsetinib), R289, and Ocadusertib (Systemic) - Eli Lilly.
Sector
PHARMACEUTICAL PREPARATIONS
Employees
174
Headquarters
SOUTH SAN FRANCISCO, CA
Exchange
XNAS
Systematic competitive advantage assessment based on 4yr data
This assessment is based on quantitative analysis of historical financial data and does not constitute investment advice. Moat ratings may change with industry and competitive dynamics.
First version surfaces recent SEC Forms 3, 4, and 5 activity. It does not yet parse individual buy/sell transactions.
Capital Structure
Cash Flow
Disclaimer: This is not financial advice. Data sourced from SEC EDGAR and Polygon.io. Past performance does not guarantee future results. Always conduct your own research before making investment decisions.